Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NB129
- Development stage
- Preclinical
- Lead developer
- Nanomerics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intranasal
01
Overview
NB129 is a preclinical-stage intranasal nanoparticle powder formulation being developed by Nanomerics for the treatment of Parkinson's Disease. The drug utilizes Nanomerics' proprietary Molecular Envelope Technology (MET) to encapsulate a small molecule therapeutic within nanoparticles, which are then delivered using the Naltos delivery device. This single-use, disposable system uses inert gas to propel the nanoparticle powder through the nasal passages, facilitating nose-to-brain delivery via the olfactory and trigeminal nerve pathways. This approach is designed to bypass the blood-brain barrier and deliver the active pharmaceutical agent directly to the central nervous system, potentially addressing dopamine deficiencies associated with Parkinson's Disease while minimizing systemic side effects.
- Brand names
- Naltos Nasal Powder
- Other names
- Naltos
Beyond the preview
Go deeper on NB129.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NB129.